The apoptotic and proliferation rate of tumour budding cells in colorectal cancer outlines a heterogeneous population of cells with various impacts on clinical outcome

Histopathology

Volumn 64, Issue 4, 2014, Pages 577-584

  Dawson, Heather ^a   Koelzer, Viktor H ^a   Karamitopoulou, Eva ^a   Economou, Mary ^a   Hammer, Caroline ^a   Muller, Dominique Elisabeth ^a   Lugli, Alessandro ^a   Zlobec, Inti ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Anoikis; Apoptosis; Colorectal cancer; Proliferation; Tumour budding

Indexed keywords

B RAF KINASE; CASPASE 3; K RAS PROTEIN; KI 67 ANTIGEN; M30 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CELL BUDDING; CELL PROLIFERATION; CELL TYPE; COLORECTAL CANCER; COMPARATIVE STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; TISSUE MICROARRAY; TISSUE SECTION; TUMOR BUDDING CELL; VERY ELDERLY;

ANOIKIS; APOPTOSIS; COLORECTAL CANCER; PROLIFERATION; TUMOUR BUDDING;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CASPASE 3; CELL PROLIFERATION; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-18; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PEPTIDE FRAGMENTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84893349927     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12294     Document Type: Article

References (18)

1. Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 2002; 40; 127-132.
2. Ueno H, Price AB, Wilkinson KH, Jass JR, Mochizuki H, Talbot IC. A new prognostic staging system for rectal cancer. Ann. Surg. 2004; 240; 832-839.
3. Tanaka M, Hashiguchi Y, Ueno H, Hase K, Mochizuki H. Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for stage ii, t3 colon cancer. Dis. Colon Rectum 2003; 46; 1054-1059.
4. Kanazawa H, Mitomi H, Nishiyama Y et al. Tumour budding at invasive margins and outcome in colorectal cancer. Colorectal Dis. 2008; 10; 41-47.
5. Wang LM, Kevans D, Mulcahy H et al. Tumor budding is a strong and reproducible prognostic marker in t3n0 colorectal cancer. Am. J. Surg. Pathol. 2009; 33; 134-141.
6. Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget 2010; 1; 651-661.
7. Brabletz T, Jung A, Hermann K, Gunther K, Hohenberger W, Kirchner T. Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol. Res. Pract. 1998; 194; 701-704.
8. Tiwari N, Gheldof A, Tatari M, Christofori G. EMT as the ultimate survival mechanism of cancer cells. Semin. Cancer Biol. 2012; 22; 194-207.
9. Jass JR, Barker M, Fraser L et al. APC mutation and tumour budding in colorectal cancer. J. Clin. Pathol. 2003; 56; 69-73.
10. Brabletz T. To differentiate or not - routes towards metastasis. Nat. Rev. Cancer 2012; 12; 425-436.
11. Jung A, Schrauder M, Oswald U et al. The invasion front of human colorectal adenocarcinomas shows co-localization of nuclear beta-catenin, cyclin d1, and p16ink4a and is a region of low proliferation. Am. J. Pathol. 2001; 159; 1613-1617.
12. Karamitopoulou E, Zlobec I, Kolzer V et al. Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer. Mod. Pathol. 2013; 26; 295-301.
13. Koelzer VH, Karamitopoulou E, Dawson H, Kondi-Pafiti A, Zlobec I, Lugli A. Geographic analysis of rkip expression and its clinical relevance in colorectal cancer. Br. J. Cancer 2013; 108; 2088-2096.
14. Varga Z, Diebold J, Dommann-Scherrer C et al. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A qa study of the Swiss Working Group of Breast- and gynecopathologists. PLoS ONE 2012; 7; e37379.
15. Rubio CA. Arrest of cell proliferation in budding tumor cells ahead of the invading edge of colonic carcinomas. A preliminary report. Anticancer Res. 2008; 28; 2417-2420.
16. Sweeney KJ, Sarcevic B, Sutherland RL, Musgrove EA. Cyclin d2 activates CDK2 in preference to CDK4 in human breast epithelial cells. Oncogene 1997; 14; 1329-1340.
17. Wassermann S, Scheel SK, Hiendlmeyer E et al. P16ink4a is a beta-catenin target gene and indicates low survival in human colorectal tumors. Gastroenterology 2009; 136; 196-205.e192.
18. Guadamillas MC, Cerezo A, Del Pozo MA. Overcoming anoikis - pathways to anchorage-independent growth in cancer. J. Cell Sci. 2011; 124; 3189-3197.